Abecma transplant drug
Ended Awarded Last action
- Contract number
- 36C24926N0244
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 9
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $338,933
Award facts
- Contract value 100% obligated
- $338,932.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lawrenceville, Lawrence Township, NJ 08648, USA
Award details come from SAM.gov/FPDS.
About this award
Bristol-Myers Squibb Company has been awarded a delivery order valued at $338,932.84 by the Department of Veterans Affairs' Veterans Integrated Service Network 9 for the supply of ABECMA, an advanced chimeric antigen receptor (CAR) T cell therapy used in the treatment of certain blood cancers, including non-Hodgkin lymphoma and multiple myeloma. The award is issued under a firm fixed-price contract structure with an ultimate completion date of March 4, 2026, and the pharmaceutical product will be delivered to a facility in Lawrenceville, New Jersey. This delivery order represents a child contract issued under Bristol-Myers Squibb's larger Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), which carries a substantial ceiling value of approximately $12.3 billion and extends through April 30, 2029.
This award carries no set-aside designation, reflecting Bristol-Myers Squibb's status as a large biopharmaceutical manufacturer with established capability to supply specialized oncology and immunotherapy treatments to federal healthcare systems. The delivery order supports the VA's mission of providing advanced medical care to eligible veterans through access to cutting-edge cellular therapies. Bristol-Myers Squibb has been consistently selected to deliver similar specialized cancer treatments under multiple delivery orders across various Veterans Integrated Service Networks, demonstrating the company's critical role as a supplier of innovative pharmaceutical solutions within the federal healthcare procurement framework.
Quick answers
Who was awarded contract 36C24926N0244?
36C24926N0244 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 9 (Veterans Health Administration) on December 5, 2025.
How much is contract 36C24926N0244 worth?
The government has obligated $338,933 on 36C24926N0244.
Is contract 36C24926N0244 an order under another contract?
Yes. 36C24926N0244 is a delivery order under 36F79724D0101, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24926N0244 competed?
The extent of competition for 36C24926N0244 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award